Research Paper Volume 13, Issue 23 pp 25089—25105

The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism


Figure 6. Reactivation of mTOR reverses the anti-tumor effects of puerarin. (A, B) The proliferation of puerarin-treated PDACs with or without MHY1485 treatment was analyzed by the colony formation assay. (C) Protein expression of c-Myc in puerarin-treated PDACs with or without MHY1485 treatment. (D, E) The migration ability of puerarin-treated PDACs in different groups was determined by the wound healing assay. (F, G) The invasion ability of puerarin-treated PDACs was analyzed by the transwell chamber assay. (H) Protein expression of vimentin and α-SMA in puerarin-treated PDACs. (I) Protein expression of Snail1 and Slug in puerarin-treated PDACs. The data are presented as the mean ± standard deviation and were analyzed by one-way ANOVA with Bonferroni’s post-hoc test and two-sided Student’s t-test. *p < 0.05, **p < 0.01, and ***p < 0.001.